Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Current Opinion in Pharmacology|January 27, 2020
Next-generation drug repurposing using human genetics and network biologySerguei Nabirotchkin, Alex E Peluffo, Philippe Rinaudo, et al.Journal of Neuroscience Research|August 21, 2020
Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosisLydie Boussicault, Julien Laffaire, Peter Schmitt, et al.Journal of Alzheimer'S Disease : JAD|July 11, 2022
Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's DiseaseSerguei Nabirotchkin, Jan Bouaziz, Fabrice Glibert, et al.Plos One|January 17, 2019
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)Thomas Prukop, Jan Stenzel, Stephanie Wernick, et al.Scientific Reports|November 7, 2015
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's diseaseRodolphe Hajj, Aude Milet, Damien Toulorge, et al.Journal of Neuropathology and Experimental Neurology|February 7, 2018
Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the DisorderMathilde Duchesne, Aurore Danigo, Laurence Richard, et al.Scientific Reports|January 9, 2015
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapyIlya Chumakov, Serguei Nabirotchkin, Nathalie Cholet, et al.Orphanet Journal of Rare Diseases|December 11, 2014
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathyIlya Chumakov, Aude Milet, Nathalie Cholet, et al.Journal of Neuroscience Research|June 27, 2020
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) ratsThomas Prukop, Stephanie Wernick, Lydie Boussicault, et al.Orphanet Journal of Rare Diseases|December 19, 2014
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AShahram Attarian, Jean-Michel Vallat, Laurent Magy, et al.Pageof 1